Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

The S&P 500 rallied in the wake of last week's election results, climbing 3.8% since Nov. 5 at Wednesday's prices. But not ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Dow has been struggling to grow for several quarters. Keytruda now makes up close to half of Merck's revenue. As you can see ...

Vitamins and mineral supplements can help address nutritional deficiencies that commonly affect people who have Crohn’s disease. Here's what your doctor may recommend.

Is India’s booming healthcare market part of your strategy, or are you overlooking a crucial opportunity? This is a question that U.S. healthcare companies should be pondering as India’s health and ...

Several African and ex-Soviet countries have expressed interest in buying Russia's vaccine against smallpox and mpox viruses, ...

MERCK lowered the top end of its full-year sales guidance after demand for its HPV vaccine fell for a second straight quarter ...

Despite Merck & Co. homing in on approval for its ... Sanofi saw revenues for its consumer health arm, Opella, grow 7.9%. Earlier this week, Sanofi confirmed it had entered exclusive negotiations ...